The diversity of pathways with which GSK-3β interacts (e.g. Wnt/β-catenin, PI3K/Akt, Ras/Raf/MEK/ERK and others), makes it a key therapeutic target for leukemia and other diseases [42]. This evidence concerns the gene GSK3B and leukemia.